**Tutorial Assignment 2**

Dawn Opert  
OPRNET001

PSY3011S: Clinical Psychology II

Katya Kee-Tui

26 September 2022

**Plagiarism Declaration**

PLAGIARISM

This means that you present substantial portions or elements of another’s work, ideas or data as your own, even if the original author is cited occasionally. A signed photocopy or other copy of the Declaration below must accompany every piece of work that you hand in.

1. I know that plagiarism is wrong. Plagiarism is to use the work of another and pass it off as my own.
2. I have used the American Psychological Association formatting for citation and referencing. Each significant contribution to, and quotation in, this essay/project/report from the work or works of other people has been attributed, cited and referenced.
3. This essay/project/report is my own work.
4. **I have not allowed, and will not allow anyone to copy my work with the intention of passing it off as their own work.**

* **Signed:** Dawn Opert
* **Date:** 25 September 2022
* **Introduction**
* Disruptive Mood Dysregulation Disorder (DMDD) is a mood disorder that is characterised by severe temper outbursts and persistent irritability, most of the time, across multiple contexts (American Psychiatric Association [APA], 2013; Baweja et al., 2016; Frances, 2013; Lochman et al., 2015). When it was initially included in the DSM-5, there was a growing recognition of a pandemic of over-diagnosis of Bipolar Disorder among children who displayed tempers (Baweja et al., 2016; Lochman et al., 2015). DMDD was meant to fix this, but threatens to introduce a host of new problems instead. Criticism of the inclusion ranges from a lack of valid studies to support the disorder to worries that the diagnostic criteria of DMDD create a real risk that it will be over-diagnosed (Baweja et al., 2016; Frances, 2013; Lochman et al., 2015). As above, this essay began with the background and context of DMDD. Following, this essay will present and discuss why DMDD should remain in the DSM and why it should not. Then, this essay will summarize the literature, and I will explain why I think that DMDD fails to adequately solve the problem it was created to deal with, and outline some potential alternatives.
* **Advantages and Disadvantages**
* Prior to the DSM-5, Bipolar Disorder (BD) in children was used to explain to some degree impairment caused by irritability, anger, and temper outbursts (Baweja et al., 2016; Mahli and Bell, 2019). The rising rate of diagnoses for BD in children coincided with increased inappropriate and unsafe use of adult antipsychotics on children (Baweja et al., 2016; Frances, 2013; Lochman et al., 2015; Mahli and Bell, 2019). However, the impairment and harm that this over-diagnosis was trying to address is real, the chronic irritability and anger, the outbursts do cause these children harm and they should be given treatment of some kind (Baweja et al., 2016). Clearly this is an issue that needs to be resolved, there are children that experience impairment that harms them, but they are also harmed by the diagnosis of BD. The creation of DMDD theoretically fixes this error by creating a new construct that describes this impairment without attaching itself to BD and adult antipsychotics (Baweja et al., 2016; Frances, 2013; Mahli and Bell, 2019). However, DMDD introduced a number of new problems. Firstly, the disorder was included based on very little research of any validity, and what research did exist was originally for a testing construct called Severe Mood Dysregulation, which shared only some of the same criteria as DMDD (Baweja et al., 2016; Frances, 2013; Lochman et al., 2015; Mahli and Bell, 2019). Furthermore, there is an issue with the construct itself. The only aspect of DMDD that cannot be accounted for in Oppositional Defiant Disorder (ODD) is irritability, to the point that if one ignores the comorbidity restriction on DMDD, almost all children with DMDD would simply have an ODD diagnosis (Baweja et al., 2016; Lochman et al., 2015; Mahli and Bell, 2019; Mayes et al., 2016; Mayes et al., 2019). Irritability is the only symptom of DMDD that does not exist in ODD (APA, 2013). However, it is a feature of many other mood and behavioural disorders, and is often a reaction to the symptoms of another disorder (Mahli and Bell, 2019; Mayes et al., 2016; Mayes et al., 2019). Additionally, there is no clear definition of ’temper outbursts’ and how to distinguish them from normal expressions of a child’s emotions at their development level (Baweja et al., 2016; Frances, 2013; Mahli and Bell, 2019). The duration and age restrictions require that clinicians diagnose children based on the children’s guardians’ impressions and their own impressions (Mahli and Bell, 2019). DMDD does not have clear treatment guidelines, and oftentimes clinicians are left to figure out how to treat children on their own, more often than not with antipsychotics and antidepressants (Mahli and Bell, 2019). As a result, in practice there is incredibly little agreement between clinicians on individual cases, and therefore a real threat of DMDD itself becoming massively over-diagnosed (Frances, 2013; Lochman et al., 2015; Mahli and Bell, 2019). Essentially, DMDD has created the same problem that it was originally designed to fix.
* **Conclusion**
* While DMDD was included for a noble cause, reducing the danger an inappropriate BD diagnosis would have on a child, its inclusion seems ill-informed. There is an alternative route that can be taken, recommended by the task-force for the World Health Organization's ICD-11. Instead of an unnecessary new construct, the ICD-11 simply added an addendum to ODD that specified whether or not the child had irritability, the only symptom that ODD does not share with DMDD (Lochman et al., 2015; Mahli and Bell, 2019; Mayes et al., 2016; Mayes et al., 2019). This was supported by robust empirical data, and achieved its goal without adding an entirely new vector for misdiagnosis (Mayes et al., 2016; Mayes et al., 2019). Finally, ODD already has a number of clear treatments that are useful for children with DMDD, so there is significantly less risk of misdiagnosis leading to severely negative outcomes (Lochman et al., 2015; Mayes et al., 2016; Mayes et al., 2019).

**References**

American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders: DSM-5 (5th ed.)*.

Baweja, R., Mayes, S., Hameed, U., & Waxmonsky, J. (2016). Disruptive mood dysregulation disorder: Current insights. *Neuropsychiatric Disease and Treatment,* (12), 2115–2124. https://doi.org/10.2147/NDT.S100312

Frances, A. (2013). *Saving normal: An insider’s revolt against out-of-control psychiatric diagnosis , DSM-5, big pharma, and the medicalization of ordinary life.* Harper Collins.

Lochman, J., Evans, S., Burke, J., Roberts, M., Fite, P., Reed, G., de la Peña, F., Matthys, W., Ezpeleta, L., Siddiqui, S., & Garralda, M. (2015). An empirically based alternative to DSM-5’s disruptive mood dysregulation disorder for ICD-11. *World Psychiatry, 14* (1), 30–33. https://doi.org/10.1002/wps.20176

Mahli, G., & Bell, E. (2019). Fake views: DMDD, indeed! *Australian & New Zealand Journal of Psychiatry, 53* (7), 706–710. https://doi.org/10.1177/0004867419863162

Mayes, S., Calhoun, S., Waxmonsky, J., Kokotovich, C., Baweja, R., Lockridge, R., & Bixler, E. (2019). Demographic differences in disruptive mood dysregulation disorder symptoms in adhd, autism, and general population samples. *Journal of Attention Disorders, 23* (8), 849–858. https://doi.org/10.1177/1087054716664409

Mayes, S., Waxmonsky, J., Calhoun, S., & Bixler, E. (2016). Disruptive mood dysregulation disorder symptoms and association with oppositional defiant and other disorders in a general population child sample. *Journal of Child and Adolescent Psychopharmacology, 26* (2), 101–106. <https://doi.org/10.1089/cap.2015.0074>